PHARMAC secures significant savings for New Zealand’s DHBs on biologic drug

4 December 2014

A new agreement for a high cost biologic drug will yield considerable savings for District Health Boards (DHBs) over the next five years, says PHARMAC, New Zealand’s Pharmaceutical Management Agency.

Infliximab (Johnson & Johnson’s [NYSE: JNJ] Remicade) is a monoclonal antibody, one of the so-called “targeted drugs” used to treat auto-immune conditions like rheumatoid arthritis, inflammatory bowel diseases, and psoriasis. It is a high cost drug used in hospitals, with current spending in the region of NZ$15 million ($11.8 million) per year and growing rapidly.

Price reduction with the advent of biosimilars

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK